Literature DB >> 11313986

Regulation of the Cdc25A gene by the human papillomavirus Type 16 E7 oncogene.

S C Katich1, K Zerfass-Thome, I Hoffmann.   

Abstract

Cdc25A is a tyrosine phosphatase that is involved in the regulation of the G1/S phase transition by activating cyclin E/Cdk2 and cyclin A/Cdk2 complexes through removal of inhibitory phosphorylations. The E6 and E7 oncoproteins of the high-risk human papillomaviruses (HPV) interact with and functionally abrogate the p53 and pRB proteins, respectively. In the present study we have investigated the regulation of the Cdc25A promoter during G1 and S-phases of the cell cycle and by the HPV-16 E7 oncoprotein. Serum induction leads to a derepression of the Cdc25A promoter and can be mediated through two E2F binding sites, E2F-A and E2F-C. While E2F-A is by both E2F1 and E2F4, E2F-C is regulated only by E2F1. The Cdc25A promoter is transactivated by the E7 oncogene of HPV-16. Furthermore, Cdc25A levels are highly increased in E7-expressing cell lines. Inducible expression of E7 leads to an immediate increase in Cdc25A protein levels. These data suggest that Cdc25A may be a critical target of HPV-16 E7 in the disruption of the G1/S phase transition.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313986     DOI: 10.1038/sj.onc.1204130

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  18 in total

1.  Microarray-based analysis of cell-cycle gene expression during spermatogenesis in the mouse.

Authors:  Dipanwita Roy Choudhury; Chris Small; Yufeng Wang; Paul R Mueller; Vivienne I Rebel; Michael D Griswold; John R McCarrey
Journal:  Biol Reprod       Date:  2010-07-14       Impact factor: 4.285

2.  High-risk human papillomavirus type 16 E7 oncogene associates with Cdc25A over-expression in oral squamous cell carcinoma.

Authors:  Ujjal Kumar Bhawal; Masaru Sugiyama; Yuji Nomura; Masahiko Sawajiri; Keiichi Tsukinoki; Masa-Aki Ikeda; Hiroki Kuniyasu
Journal:  Virchows Arch       Date:  2006-11-17       Impact factor: 4.064

3.  Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest.

Authors:  Don X Nguyen; Thomas F Westbrook; Dennis J McCance
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 4.  The role of Cdc25A in the regulation of cell proliferation and apoptosis.

Authors:  Tao Shen; Shile Huang
Journal:  Anticancer Agents Med Chem       Date:  2012-07       Impact factor: 2.505

Review 5.  Human papillomavirus oncoproteins: pathways to transformation.

Authors:  Cary A Moody; Laimonis A Laimins
Journal:  Nat Rev Cancer       Date:  2010-07-01       Impact factor: 60.716

6.  The PTPN14 Tumor Suppressor Is a Degradation Target of Human Papillomavirus E7.

Authors:  Anita Szalmás; Vjekoslav Tomaić; Om Basukala; Paola Massimi; Suruchi Mittal; József Kónya; Lawrence Banks
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

7.  A bioinformatics-based strategy identifies c-Myc and Cdc25A as candidates for the Apmt mammary tumor latency modifiers.

Authors:  Diana Cozma; Luanne Lukes; Jessica Rouse; Ting Hu Qiu; Edison T Liu; Kent W Hunter
Journal:  Genome Res       Date:  2002-06       Impact factor: 9.043

8.  Inactivation of both the retinoblastoma tumor suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells.

Authors:  Anna-Marija Helt; Jens Oliver Funk; Denise A Galloway
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  SIRT6 inhibits colorectal cancer stem cell proliferation by targeting CDC25A.

Authors:  Wenguang Liu; Manwu Wu; Hechun Du; Xiaoliang Shi; Tao Zhang; Jie Li
Journal:  Oncol Lett       Date:  2018-02-07       Impact factor: 2.967

10.  Inhibition of E2F1 activity and cell cycle progression by arsenic via retinoblastoma protein.

Authors:  Lynn A Sheldon
Journal:  Cell Cycle       Date:  2017-09-28       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.